Most experts would treat you for one to two weeks, then taper the medicine off over a few weeks. The side effects of this dose of steroids are modest if it does not need to be frequently repeated.

Rilzabrutinib (Wayrilz; Sanofi), a BTK inhibitor, targets immune-mediated platelet destruction in immune thrombocytopenia (ITP) and has demonstrated a favorable safety profile.

The FDA expanded the approval of Cablivi to include pediatric patients 12 years and older with acquired thrombotic thrombocytopenic purpura.

Following the FDA approval of rilzabrutinib (Wayrilz; Sanofi) for immune thrombocytopenia (ITP), a rare autoimmune disorder, David Kuter, MD, DPhil, highlights the most pressing a ...

"The treatment paradigm of ITP is slowly shifting due to expanding experience with earlier use of TPO-RAs and TPO-mimetics in chronic and refractory ITP…Most of these agents are oral and better ...

New prospective research builds on a previous study that showed guidelines aren’t the main driver of treatment selection in pediatric patients with ITP. Of 12 potential reasons for prescribing ...

What can you tell me about the cause and treatment of immune thrombocytopenia purpura (ITP)? I am a 71-year-old male, ...

What can you tell me about the cause and treatment of immune thrombocytopenia purpura (ITP)? I am a 71-year-old male, and ...

Immune thrombocytopenia (ITP) is a rare condition that causes a low platelet count. People with ITP can experience life threatening bleeding if the condition is not treated. Many people with ITP go ...

LBA-2: Primary results from VAYHIT2, a randomized, double-blind, phase 3 trial of ianalumab plus eltrombopag versus placebo plus eltrombopag in patients with primary immune thrombocytopenia (ITP) who ...

Sanofi ($SNYNF) announced an update on their ongoing clinical study. Study Overview Sanofi has completed an observational study titled “Cognitive ...